| Previous Close | 4.76 |
| Open | 4.84 |
| Bid | 4.98 x 900 |
| Ask | 5.01 x 1400 |
| Day's Range | 4.75 - 5.03 |
| 52 Week Range | 2.02 - 13.49 |
| Volume | 104,585 |
| Avg. Volume | 431,816 |
| Market Cap | 534.54M |
| Beta (5Y Monthly) | 2.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020 (Article 223-16 of the General Regulations of the.
Montrouge, France, April 30, 2020 DBV Technologies Reports March 31, 2020 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a.
Montrouge, France, April 20, 2020 DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting Shareholders approve all proposed resolutions DBV.
Monthly information regarding the.
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced that it will hold its Ordinary and Extraordinary General Meeting in a closed virtual session on April 20, 2020 at 8:30 a.m. CEST. In accordance with past General Meetings, the event will be conducted in French. The Company values the safety of all shareholders and employees.
Montrouge, France, March 30, 2020 Ordinary and Extraordinary General Meeting of April 20, 2020 Procedures for Obtaining Preparatory Documents for the General Meeting.
Montrouge, France, March 20, 2020 DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F DBV Technologies (Euronext:.
Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020.
NEW YORK, NY / ACCESSWIRE / March 17, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DBV Technologies S.A. ("DBV" or the Company") ...
NEW YORK, March 17, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (“DBV” or the “Company”) (NASDAQ: DBVT). Such investors are.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that during its ongoing review of the Biologics License Application (BLA) for investigational Viaskin™ Peanut, it has identified questions regarding efficacy, including the impact of patch-site adhesion. The Company is in communication with the FDA regarding the potential submission of additional information on patch-site adhesion from its clinical program as well as long-term efficacy results from the three-year open-label extension study, PEOPLE, to answer FDA’s questions, as part of the ongoing BLA review.
Montrouge, France, March 4, 2020 DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update Advisory Committee meeting to be held on May.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery of an aggregate of 338,687 additional ordinary shares in the form of 677,374 American Depositary Shares (“ADSs”), on the same terms and conditions as the securities previously sold in the global offering which settled on February 4, 2020, pursuant to the partial exercise of the underwriters’ option to purchase additional ordinary shares in the form of ADSs (the “Option Closing”). Each ADS represents the right to receive one-half of one ordinary share.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the underwriters for its previously announced global offering have partially exercised their option to purchase 338,687 additional ordinary shares in the form of 677,374 American Depositary Shares (“ADSs”), at an offering price of $10.25 per ADS, before deducting commissions and estimated offering expenses (the “Option”). Each ADS represents the right to receive one-half of one ordinary share, and the offering price of $10.25 per ADS corresponds to a price of €18.63 per ordinary share (on the basis of an exchange rate of $1.0999 = €1.00).
Montrouge, France, February 24, 2020 DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 DBV Technologies (Euronext: DBV – ISIN:.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has announced an Allergenic Products Advisory Committee meeting to be held on May 15, 2020 to discuss the Biologics License Application (BLA) for Viaskin™ Peanut. Viaskin Peanut, which is based on epicutaneous immunotherapy (EPIT), is an investigational drug currently under review by the FDA as a treatment for peanut allergy in children.
Montrouge, France, February 10, 2020 DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN:.
Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020 (Article 223-16 of the.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Pascal Wotling as its Chief Technical Operations Officer (CTOO), effective April 1, 2020. Pascal will be responsible for manufacturing, supply chain and new product process development, and will serve as a member of the Executive Committee, reporting to Daniel Tassé, Chief Executive Officer of DBV Technologies.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery on February 4, 2020 of an underwritten global offering of an aggregate of 7,500,000 ordinary shares in (i) a public offering of 4,535,581 ordinary shares in the form of 9,071,162 American Depositary Shares (“ADSs”) in the United States, Canada and certain countries outside Europe at a public offering price of $10.25 per ADS (on the basis of an exchange rate of $1.0999 = €1.00), and (ii) an offering exclusively addressed to qualified investors in Europe (including France) of 2,964,419 ordinary shares at an offering price of €18.63 per ordinary share (together, the “Global Offering”). The Company has granted the underwriters a 30-day overallotment option allowing them to purchase, on the same terms and conditions, up to 1,125,000 additional ordinary shares in the form of 2,250,000 ADSs.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the pricing of a global offering of an aggregate of 7,500,000 ordinary shares in (i) a public offering of 4,535,581 ordinary shares in the form of 9,071,162 American Depositary Shares (ADSs) in the United States, Canada and certain countries outside of Europe at a public offering price of $10.25 per ADS (on the basis of an exchange rate of $1.0999 = €1.00) and (ii) an offering exclusively addressed to qualified investors in Europe (including France) of 2,964,419 ordinary shares at a public offering price of €18.63 per ordinary share (together, the “Global Offering”). The price at which the ordinary shares (including in the form of ADSs) will be sold in the Global Offering is equal to the weighted-average of the trading prices of the Company’s ordinary shares on Euronext Paris over the three (3) trading days prior to the launch of the Global Offering (i.e.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its intention to launch, subject to market conditions, a global offering of new ordinary shares, which may be in the form of American Depositary Shares (“ADSs”), in an aggregate amount of $125.0 million. The global offering will be comprised of a public offering of ordinary shares in the form of ADSs in the United States, Canada and certain countries outside of Europe and an offering exclusively addressed to qualified investors in Europe (including France).
AMF REGULATED INFORMATIONMontrouge, France, January 15, 2020 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN:.
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive topline results of the three-year, open-label extension of the Phase III PEPITES trial (PEOPLE) evaluating the long-term efficacy and safety of investigational Viaskin® Peanut in peanut-allergic children ages 4 to 11 years. The results demonstrate long-term clinical benefit as shown by an increase in eliciting dose (ED), which may decrease the chance of reacting to an accidental peanut exposure.
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Ramzi Benamar as its Chief Financial Officer (CFO), effective January 6, 2020. Ramzi will serve as a member of the Executive Committee and report to Daniel Tassé, Chief Executive Officer of DBV Technologies.